Hypothesis

Intermittent, pulsed NMN administration timed to the early refeeding phase after a short fast will produce a transient surge of hepatic NAMPT activity that preferentially raises nuclear NAD+ and activates SIRT1, whereas continuous daily dosing yields only cytosolic NAD+ elevation and limited SIRT1 engagement.

Rationale

• Human studies show oral NR or NMN raises whole‑blood NAD+ but do not measure SIRT1 activation [Chronic oral NR supplementation at 1000 mg/day does elevate NAD+ levels in human peripheral blood mononuclear cells, combination supplement containing NR increased whole-blood NAD+ by 67% in 28 days while improving well-being].
• Oral NMN/NR are largely metabolized to nicotinamide before reaching systemic circulation, limiting tissue‑specific availability [Oral NMN and NR are largely converted to nicotinamide before entering systemic circulation].
• NAD+ pools are compartmentalized; nuclear NAD+ is the direct substrate for SIRT1 [NAD+ metabolism is highly compartmentalized, with concentrations varying significantly between cytosol, nucleus, and mitochondria].
• In mice, time‑restricted fasting combined with NMN boosts muscle NAD+ and endurance, and hepatic NAMPT is a key mediator of fasting benefits [combining time‑restricted fasting with NMN synergistically enhanced muscle NAD+, endurance, and beneficial gut microbiota in mice, the enzyme NAMPT that generates NMN drives critical metabolic aspects of fasting in the liver].
• No study has tested pulsed NMN/NR dosing in any species; all human trials use continuous daily administration.

Mechanistic Insight

Fasting suppresses hepatic NAMPT activity, lowering nuclear NAD+ synthesis. Upon refeeding, a rapid increase in intracellular nicotinamide (from dietary protein turnover) provides substrate for NAMPT. If an NMN pulse is delivered at this moment, the enzyme can convert the exogenous NMN to NAD+ before it is shunted to the salvage pathway that yields nicotinamide. This creates a brief, high‑amplitude spike of nuclear NAD+ that exceeds the Km of SIRT1, leading to enzyme activation and downstream deacetylation of targets such as PGC‑1α and FOXO3. Continuous dosing, by contrast, maintains a modest, steady NAD+ rise that is buffered by cytosolic NAD+ consuming enzymes (CD38, PARPs) and thus fails to reach the threshold needed for robust SIRT1 activation in the nucleus.

Predictions and Testable Experiments

1. Primary outcome – Nuclear NAD+ levels in peripheral blood mononuclear cells (PBMCs) isolated after a 16‑hour fast will be significantly higher 2 h after a single 500 mg NMN pulse given at the start of refeeding compared with the same total daily dose split into two 250 mg doses given with meals.
   • Assay: Subcellular fractionation followed by LC‑MS/MS quantification of NAD+ in nuclear vs cytosolic fractions.
2. Secondary outcome – SIRT1 activity (measured by acetyl‑p53 deacetylation assay) will increase ≥30 % in the pulsed condition but remain unchanged in the continuous condition.
3. Exploratory outcome – Expression of SIRT1‑dependent genes (SOD2, CAT, PPARGC1A) in PBMCs will rise only after pulsed dosing.

Study design – Randomized, crossover trial in 20 healthy adults. Each participant completes two 7‑day arms separated by a 2‑week washout: (A) pulsed NMN (500 mg at hour 0 of refeeding after a 16‑hour fast) and (B) continuous NMN (250 mg with breakfast and dinner). Blood drawn at baseline, 2 h, 6 h, and 24 h post‑dose on day 1 and day 7.

Potential Outcomes and Falsifiability

• If nuclear NAD+ and SIRT1 activation are markedly greater in the pulsed arm, the hypothesis is supported, indicating that timing NMN to the post‑fast NAMPT window can overcome compartmentalization limits.
• If no difference is observed between arms, or if continuous dosing yields equal or higher nuclear NAD+, the hypothesis is falsified, suggesting that oral NMN cannot preferentially access the nuclear pool regardless of dosing pattern.

This framework converts existing bioavailability and compartmentalization data into a concrete, falsifiable protocol that directly tests whether pulsed NAD+ precursor supplementation can achieve the SIRT1 activation presumed from rodent work.